Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients

European Journal of Cancer, Supplement

Volumn 5, Issue 2, 2007, Pages 5-12

  Bucaneve, Giampaolo ^a   Castagnola, Elio ^b   Viscoli, Claudio ^c   Leibovici, Leonard ^d   Menichetti, Francesco ^e  

^a POLICLINICO MONTELUCE   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d Department of Medicine E Rabin Medical Center ^*  (Israel)

^e CISANELLO HOSPITAL   (Italy)

Author keywords

Acute leukaemia; Antibiotic prophylaxis; Ciprofloxacin; Haematopoietic stem cell transplantation (HSCT); Levofloxacin; Neutropenia; Norfloxacin; Ofloxacin; Quinolones

Indexed keywords

BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ENOXACIN; GLYCOPEPTIDE; LEVOFLOXACIN; MACROLIDE; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PLACEBO; QUINOLINE; RIFAMPICIN; ROXITHROMYCIN;

ACUTE LEUKEMIA; ANTIBIOTIC PROPHYLAXIS; APLASTIC ANEMIA; ARTICLE; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CHRONIC LEUKEMIA; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE SEQUENCE; DRUG MEGADOSE; EUROPE; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOMA; MEDICAL PRACTICE; META ANALYSIS; MULTIPLE MYELOMA; MYELODYSPLASIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SYSTEMATIC REVIEW;

EID: 34547508230     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2007.06.002     Document Type: Article

References (39)

1. Hughes W.T., Armstrong D., Bodey G.P., et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34 (2002) 730-751
2. Sleijfer D.T., Mulder N.H., de vries-Hospers H.G., et al. Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur J Cancer 16 (1980) 859-869
3. Karp J.E., Merz W.G., Hendricksen C., et al. Oral norfloxacin for prevention of Gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 106 (1987) 1-7
4. Hartlapp J.H. Antimicrobial prophylaxis in immunocompromised patients. Drugs 34 Suppl. 1 (1987) 131-133
5. Lew M.A., Kehoe K., Ritz J., et al. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation 51 (1991) 630-636
6. Sampi K., Maseki N., and Hattori M. A comparison of nystatin with norfloxacin for prevention of infection after consolidation therapy in patients with acute leukemia or autologous bone marrow transplantation: a randomized study. Gan to Kagaku Ryoho 19 (1992) 823-826 [in Japanese]
7. Shhroeder M., Schessel C., Selbach J., et al. Antibiotic prophylaxis with gyrase inhibitors during cytostatically induced granulocytopenias in patients with solid tumors a double-blind prospective randomized study. Onkologie 15 (1992) 476-479
8. Maiche A.G., and Muhonen T. Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients. Eur J Cancer 29A (1993) 1403-1405
9. Talbot G.H., Casileth P.A., Paradiso L., et al. Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group. Antimicrob Agents Chemother 37 (1993) 474-482
10. Yamada T., Dan K., and Nomura T. Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B. Intern Med 2 (1993) 710-715
11. Brodsky A.L., Minissale C.J., Melero M.J., et al. Prophylaxis with fluoroquinolones in patients with neutropenia. Medicina (B Aires) 53 (1993) 401-407
12. Carlson J.W., Fowler J.M., Mitchell S.K., et al. Chemoprophylaxis with ciprofloxacin in ovarian cancer patients receiving paclitaxel: a randomized trial. Gynecol Oncol 65 (1997) 325-329
13. Casali A., Veri C., Paoletti G., et al. Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin. Chemioterapia 7 (1988) 327-329
14. Thomas X., Troncy J., Belhabri A., et al. Effectiveness of combined vancomycin and pefloxacine in gastrointestinal decontamination for preventing infections after chemotherapy-induced bone marrow aplasia. A randomized double-blind study. Presse Med 29 (2000) 1745-1751
15. Tjan-HeiJnen V.C., Postmus P.E., Ardizzoni A., et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol 12 (2001) 1359-1368
16. Nenova I.S., Ananostev N.H., Goranov S.E., et al. Fluoroquinolone prophylaxis for bacterial infections in neutropenic patients with hematologic malignancies. Folia Med (Plovdiv) 43 (2001) 40-45
17. Tsutani H., Imamura S., Ueda T., et al. Prophylactic use of ofloxacin in granulocytopenic patients with hematological malignancies during post-remission chemotherapy. Intern Med 31 (1992) 319-324
18. Lee D.G., Choi S.M., Choi J.H., et al. Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial. Korean J Intern Med 17 (2002) 38-44
19. Castagnola E., Haupt R., Micozzi A., et al. Differences in the proportions of fluoroquinolone-resistant Gram-negative bacteria isolated from bacteraemic children with cancer in two Italian centres. Clin Microbiol Infect 11 (2005) 505-507
20. Bucaneve G., Micozzi A., Menicheti F., et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353 (2005) 977-987
21. Cullen M., Steven N., Billingham L., et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353 (2005) 988-998
22. Gafter-Gvili A., Fraser A., Paul M., and Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142 (2005) 979-995
23. van de Wetering M.D., de Witte M.A., Kremer L.C.M., et al. Efficay of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer 41 (2005) 1372-1382
24. Engels E.A., Lau J., and Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 16 (1998) 1179-1187
25. Cruciani M., Randazzo R., Malena M., et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 23 (1996) 795-805
26. Cruciani M., Malena M., Bosco O., et al. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 21 (2003) 4127-4137
27. Leibovici L., Paul M., Cullen M., et al. Antibiotic prophylaxis in neutropenic patients: new evidences, practical decisions. Cancer 107 (2006) 1743-1751
28. Kern W.V., Andriof E., Oethinger M., et al. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38 (1994) 681-687
29. Carratala J., Fernandez-Sevilla A., Tubau F., et al. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 20 (1995) 557-560 [discussion 561-3]
30. Somolinos N., Arranz R., Del Rey M.C., et al. Superinfections by Escherichia coli resistant to fluoroquinolones in immunocompromised patients. J Antimicrob Chemother 30 (1992) 730-731
31. Razonable R.R., Litzow M.R., Khaliq Y., et al. Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin. Clin Infect Dis 34 (2002) 1469-1474
32. Baden L.R. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 353 (2005) 1052-1054
33. Martino R., Subira M., Altes A., et al. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity. Acta Haematol 99 (1998) 206-211
34. Kern W.V., Klose K., Jellen Ritter A.S., et al. Fluoroquinolones resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 24 (2005) 111-118
35. The GIMEMA Infection Program. Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med 115 (1991) 7-12
36. D'Antonio D., Piccolomini R., Iacone A., et al. Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies. J Antimicrob Chemother 33 (1994) 837-844
37. Carlens S., Ringden O., Aschan J., et al. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination. Clin Transplant 12 (1998) 84-92
38. Xie H.J., Broberg U., Griskevivius L., et al. Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome p450 genes by ciprofloxacin. Bone Marrow Transplant 31 (2003) 197-203
39. Afsharian P., Mollgard L., Hassan Z., et al. The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma. Eur J Haematol 75 (2005) 206-211